GDC-0449-A potent inhibitor of the hedgehog pathway

被引:321
作者
Robarge, Kirk D. [1 ]
Brunton, Shirley A. [2 ]
Castanedo, Georgette M. [1 ]
Cui, Yong [1 ]
Dina, Michael S. [1 ]
Goldsmith, Richard [1 ]
Gould, Stephen E. [3 ]
Guichert, Oivin [3 ]
Gunzner, Janet L. [1 ]
Halladay, Jason [1 ]
Jia, Wei [1 ]
Khojasteh, Cyrus [1 ]
Koehler, Michael F. T. [1 ]
Kotkow, Karen [3 ]
La, Hank [1 ]
LaLonde, Rebecca L. [1 ]
Lau, Kevin [1 ]
Lee, Leslie [1 ]
Marshall, Derek [1 ]
Marsters, James C., Jr. [1 ]
Murray, Lesley J. [1 ]
Qian, Changgeng [3 ]
Rubin, Lee L. [3 ]
Salphati, Laurent [1 ]
Stanley, Mark S. [1 ]
Stibbard, John H. A. [2 ]
Sutherlin, Daniel P. [1 ]
Ubhayaker, Savita [1 ]
Wang, Shumei [1 ]
Wong, Susan [1 ]
Xie, Minli [1 ]
机构
[1] Genentech Inc, Small Mol Drug Discovery, San Francisco, CA 94080 USA
[2] Evotec, Abingdon OX14 4RX, Oxon, England
[3] Curis Inc, Cambridge, MA 02138 USA
关键词
GDC-0449; Hedgehog pathway; Small molecule inhibitor; SIGNALING PATHWAY; HUMAN HOMOLOG; MEDULLOBLASTOMA; REQUIREMENT; MUTATIONS; GROWTH; GENE;
D O I
10.1016/j.bmcl.2009.08.049
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
SAR for a wide variety of heterocyclic replacements for a benzimidazole led to the discovery of functionalized 2-pyridyl amides as novel inhibitors of the hedgehog pathway. The 2-pyridyl amides were optimized for potency, PK, and drug-like properties by modifications to the amide portion of the molecule resulting in 31 (GDC-0449). Amide 31 produced complete tumor regression at doses as low as 12.5 mg/kg BID in a medulloblastoma allograft mouse model that is wholly dependent on the Hh pathway for growth and is currently in human clinical trials, where it is initially being evaluated for the treatment of BCC. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5576 / 5581
页数:6
相关论文
共 22 条
[1]   Medulloblastoma growth inhibition by Hedgehog pathway blockade [J].
Berman, DM ;
Karhadkar, SS ;
Hallahan, AR ;
Pritchard, JI ;
Eberhart, CG ;
Watkins, DN ;
Chen, JK ;
Cooper, MK ;
Taipale, J ;
Olson, JM ;
Beachy, PA .
SCIENCE, 2002, 297 (5586) :1559-1561
[2]   Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours [J].
Berman, DM ;
Karhadkar, SS ;
Maitra, A ;
de Oca, RM ;
Gerstenblith, MR ;
Briggs, K ;
Parker, AR ;
Shimada, Y ;
Eshleman, JR ;
Watkins, DN ;
Beachy, PA .
NATURE, 2003, 425 (6960) :846-851
[3]   Potent inhibitors of the hedgehog signaling pathway [J].
Brunton, Shirley A. ;
Stibbard, John H. A. ;
Rubin, Lee L. ;
Kruse, Lawrence I. ;
Guicherit, Oivin M. ;
Boyd, Edward A. ;
Price, Steven .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (05) :1108-1110
[4]   Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened [J].
Chen, JK ;
Taipale, J ;
Cooper, MK ;
Beachy, PA .
GENES & DEVELOPMENT, 2002, 16 (21) :2743-2748
[5]   Small molecule modulation of Smoothened activity [J].
Chen, JK ;
Taipale, J ;
Young, KE ;
Maiti, T ;
Beachy, PA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (22) :14071-14076
[6]   Teratogen-mediated inhibition of target tissue response to Shh signaling [J].
Cooper, MK ;
Porter, JA ;
Young, KE ;
Beachy, PA .
SCIENCE, 1998, 280 (5369) :1603-1607
[7]   A mouse model for medulloblastoma and basal cell nevus syndrome [J].
Corcoran, RB ;
Scott, MP .
JOURNAL OF NEURO-ONCOLOGY, 2001, 53 (03) :307-318
[8]   Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours [J].
Dahmane, N ;
Lee, J ;
Robins, P ;
Heller, P ;
Altaba, ARI .
NATURE, 1997, 389 (6653) :876-881
[9]  
Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10
[10]   Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome [J].
Hahn, H ;
Wicking, C ;
Zaphiropoulos, PG ;
Gailani, MR ;
Shanley, S ;
Chidambaram, A ;
Vorechovsky, I ;
Holmberg, E ;
Unden, AB ;
Gillies, S ;
Negus, K ;
Smyth, I ;
Pressman, C ;
Leffell, DJ ;
Gerrard, B ;
Goldstein, AM ;
Dean, M ;
Toftgard, R ;
ChenevixTrench, G ;
Wainwright, B ;
Bale, AE .
CELL, 1996, 85 (06) :841-851